MC
CRL icon

Moors & Cabot’s Charles River Laboratories CRL Stock Holding History

Moors & Cabot’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Buy
1,697
+12
+0.7% +$2.23K 0.01% 711
2025
Q4 		$336K Hold
1,685
– – 0.01% 648
2025
Q3 		$264K Hold
1,685
– – 0.01% 724
2025
Q2 		$256K Sell
1,685
-126
-7% -$16.8K 0.01% 711
2025
Q1 		$273K Sell
1,811
-3
-0.2% -$503 0.01% 672
2024
Q4 		$335K Buy
1,814
+9
+0.5% +$1.73K 0.02% 636
2024
Q3 		$356K Sell
1,805
-190
-10% -$39.5K 0.02% 608
2024
Q2 		$412K Buy
1,995
+18
+0.9% +$4.08K 0.02% 534
2024
Q1 		$536K Sell
1,977
-299
-13% -$71.4K 0.03% 473
2023
Q4 		$538K Sell
2,276
-5
-0.2% -$983 0.03% 443
2023
Q3 		$447K Sell
2,281
-74
-3% -$15.2K 0.03% 469
2023
Q2 		$495K Buy
2,355
+108
+5% +$21.5K 0.03% 448
2023
Q1 		$453K Buy
2,247
+18
+0.8% +$4.08K 0.03% 463
2022
Q4 		$486K Buy
2,229
+90
+4% +$19.7K 0.03% 432
2022
Q3 		$421K Buy
2,139
+151
+8% +$32.6K 0.03% 452
2022
Q2 		$425K Buy
1,988
+100
+5% +$24.4K 0.03% 458
2022
Q1 		$536K Sell
1,888
-10
-0.5% -$3.08K 0.03% 448
2021
Q4 		$715K Buy
1,898
+100
+6% +$38.9K 0.04% 369
2021
Q3 		$743K Buy
+1,798
New +$747K 0.05% 344

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Moors & Cabot's CRL Position: Q1 2026 in Review

Moors & Cabot increased its Charles River Laboratories (CRL) stake by 0.71% in Q1 2026, buying an estimated $2.23K and bringing the position to 1,697 shares worth $293K. The position accounts for 0.01% of the portfolio, ranked #711.

Moors & Cabot first reported a position in CRL in Q3 2021 and has held it in 19 quarters since. The position peaked at $743K in Q3 2021. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Moors & Cabot held 1,697 shares of Charles River Laboratories worth $293K as of Q1 2026.
  • Moors & Cabot bought 12 Charles River Laboratories shares in Q1 2026, an estimated $2.23K.
  • Charles River Laboratories made up 0.01% of Moors & Cabot's portfolio in Q1 2026, its #711 holding.
  • Moors & Cabot first reported a position in Charles River Laboratories in Q3 2021 and has held it in 19 quarters since.
  • Moors & Cabot's Charles River Laboratories position peaked at $743K in Q3 2021.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.